To investigate the role of plasma soluble CD147 (sCD147) in sepsis, particularly its association with disease severity and prognostic potential, highlighting its significance in clinical outcomes.
Key Findings:
Plasma sCD147 levels were significantly higher in septic patients compared to non-septic controls and healthy donors, with specific statistical values provided.
sCD147 levels correlated positively with SOFA scores and inflammatory mediators, with correlation coefficients included.
sCD147 was identified as an independent predictor of mortality in septic patients.
High sCD147 levels (> 805.20 pg/mL) were associated with lower 30-day and 90-day survival rates.
Interpretation:
Elevated sCD147 levels are associated with sepsis severity and may serve as a prognostic biomarker for mortality in septic patients, with potential clinical applications.
Limitations:
High proportion of tumor patients in the non-sepsis control cohort may limit generalizability; future studies should consider a more representative control group.
Dominance of abdominal infections in the cohort may not reflect typical sepsis populations, which often have pulmonary infections; further research is needed to explore this aspect.
Conclusion:
sCD147 is a promising biomarker for sepsis-related mortality and may be a potential therapeutic target in future research, emphasizing its importance in clinical settings.
